{
    "root": "1f47a6d2-fc54-4fb6-ba94-74de796a55d9",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Desvenlafaxine",
    "value": "20250312",
    "ingredients": [
        {
            "name": "DESVENLAFAXINE SUCCINATE",
            "code": "ZB22ENF0XR"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POVIDONE K90",
            "code": "RDH86HJV5Z"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "POLYETHYLENE GLYCOL 8000",
            "code": "Q662QK8M3B"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        }
    ],
    "indications": "desvenlafaxine indicated treatment adults major depressive disorder ( mdd ) [ ( 14 ) ] .",
    "contraindications": "\u2022recommended dose : 50 mg daily without food ( 2.1 ) . \u2022there evidence doses greater 50 mg per day confer additional benefit ( 2.1 ) . \u2022the 25 mg per day dose intended gradual reduction dose discontinuing treatment dosing severe renal end-stage renal disease patients ( 2.1 ) . \u2022discontinuation : reduce dose gradually whenever possible ( 2.1 ) . \u2022take tablets whole ; divide , crush , chew , dissolve ( 2.1 ) . \u2022moderate renal impairment : maximum dose 50 mg per day ( 2.2 ) . \u2022severe renal impairment end-stage renal disease : maximum dose 25 mg per day 50 mg every day ( 2.2 ) . \u2022moderate severe hepatic impairment : maximum dose 100 mg per day ( 2.3 ) .",
    "warningsAndPrecautions": "desvenlafaxine extended-release tablets available follows : 100 mg , dark brown red colored , round , biconvex tablets , debossed \u2018 l350 \u2019 one side plain side . ndc 68788-7175-3 , bottle 30 tablets . ndc 68788-7175-6 , bottle 60 tablets . ndc 68788-7175-9 , bottle 90 tablets . ndc 68788-7175-1 , bottle 100 tablets . store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) . [ usp controlled room temperature ] tablet contains 38 mg , 76 mg 152 mg desvenlafaxine succinate equivalent 25 mg , 50 mg 100 mg desvenlafaxine , respectively .",
    "adverseReactions": "\u2022 hypersensitivity desvenlafaxine succinate , venlafaxine hydrochloride excipients desvenlafaxine extended-release tablets formulation . angioedema reported patients treated desvenlafaxine [ ( 6.1 ) ] . \u2022 maois intended treat psychiatric disorders desvenlafaxine within 7 days stopping treatment desvenlafaxine contraindicated increased risk serotonin syndrome . desvenlafaxine within 14 days stopping maoi intended treat psychiatric disorders also contraindicated [ ( 2.7 ) ( 5.2 ) ] . \u2022 starting desvenlafaxine patient treated maois linezolid intravenous methylene blue also contraindicated increased risk serotonin syndrome [ ( 2.8 ) ( 5.2 ) ] .",
    "indications_original": "Desvenlafaxine is indicated for the treatment of adults with major depressive disorder (MDD) [see Clinical Studies (14)].",
    "contraindications_original": "\u2022Recommended dose: 50 mg once daily with or without food ( 2.1 ). \u2022There was no evidence that doses greater than 50 mg per day confer any additional benefit ( 2.1 ). \u2022The 25 mg per day dose is intended for a gradual reduction in dose when discontinuing treatment or dosing in severe renal and end-stage renal disease patients ( 2.1 ). \u2022Discontinuation: Reduce dose gradually whenever possible ( 2.1 ). \u2022Take tablets whole; do not divide, crush, chew, or dissolve ( 2.1 ). \u2022Moderate renal impairment: Maximum dose 50 mg per day ( 2.2 ). \u2022Severe renal impairment and end-stage renal disease: Maximum dose 25 mg per day or 50 mg every other day ( 2.2 ). \u2022Moderate to severe hepatic impairment: Maximum dose 100 mg per day ( 2.3 ).",
    "warningsAndPrecautions_original": "Desvenlafaxine Extended-Release Tablets are available as follows: \n                  \n                     100 mg, dark brown to red colored, round, biconvex tablets, debossed with \u2018L350\u2019 on one side and plain on other side.\n                  \n                  NDC 68788-7175-3, bottle of 30 tablets.\n                  NDC 68788-7175-6, bottle of 60 tablets.\n                  NDC 68788-7175-9, bottle of 90 tablets.\n                  NDC 68788-7175-1, bottle of 100 tablets.\n                  \n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F). [See USP Controlled Room Temperature]\n                  Each tablet contains\u00a038 mg, 76 mg or 152 mg of desvenlafaxine succinate equivalent to 25 mg, 50 mg\u00a0or 100 mg of desvenlafaxine, respectively.",
    "adverseReactions_original": "\u2022\tHypersensitivity to desvenlafaxine succinate, venlafaxine hydrochloride or to any excipients in the desvenlafaxine extended-release tablets formulation. Angioedema has been reported in patients treated with desvenlafaxine [see Adverse Reactions (6.1)].  \u2022\tThe use of MAOIs intended to treat psychiatric disorders with desvenlafaxine or within 7 days of stopping treatment with desvenlafaxine is contraindicated because of an increased risk of serotonin syndrome. The use of desvenlafaxine within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated [see Dosage and Administration (2.7) and Warnings and Precautions (5.2)].\n                      \u2022\tStarting desvenlafaxine in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see Dosage and Administration (2.8) and Warnings and Precautions (5.2)]."
}